Related Experiment Video

Updated: May 17, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A role for p21-activated kinase 7 in the development of gastric cancer

Jun Gu1, Keqiang Li, Maolan Li

  • 1Department of General Surgery, Xinhua Hospital, Affiliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

The FEBS Journal
|October 31, 2012
PubMed

Insights

p21-activated kinase 7 (PAK7) is upregulated in gastric cancer, promoting tumor growth by affecting cell cycle regulators. Inhibiting PAK7 may offer a new therapeutic strategy for gastric cancer patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • p21-activated kinase 7 (PAK7) is a serine/threonine protein kinase involved in cell signaling.
  • PAK7's role in cancer, particularly gastric cancer, remains largely unknown.
  • PAK7 is an effector of small GTPases Rac and CDC42.

Purpose of the Study:

  • To investigate the role of PAK7 in gastric carcinogenesis.
  • To determine if PAK7 is a potential therapeutic target for gastric cancer.

Main Methods:

  • PAK7 expression analysis in gastric cancer cell lines and tissues.
  • Lentivirus-mediated small interfering RNA (siRNA) to inhibit PAK7 expression.
  • Assessment of cell proliferation, cell cycle, and key cell cycle regulators (CDK2, CDC25A, cyclin D1).

Main Results:

  • PAK7 expression was significantly upregulated in gastric cancer cell lines and tissues compared to normal controls.
  • PAK7 knockdown using siRNA effectively reduced PAK7 expression at both mRNA and protein levels.
  • Inhibition of PAK7 led to decreased gastric cancer cell proliferation by inducing G(0)/G(1) phase cell cycle arrest.
  • Downregulation of CDK2, CDC25A, and cyclin D1 was observed following PAK7 knockdown.

Conclusions:

  • PAK7 is a novel hallmark of gastric cancer, associated with disease progression.
  • PAK7 contributes to tumor growth by influencing cell cycle regulators.
  • PAK7 represents a promising therapeutic target for gastric cancer treatment.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...